Article

Study: coffee protects against blepharospasm

People who drink coffee are less likely to develop primary late-onset blepharospasm, according to results of a multicenter case control study conducted in Italy and published online ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

London-People who drink coffee are less likely to develop primary late-onset blepharospasm, according to results of a multicenter case control study conducted in Italy and published online ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

One to two cups per day were needed for the protective effect to be seen, and the effect was proportional to the amount of coffee consumed. Also, the age of onset of the eye spasm was found to be later in patients who drank more coffee: 1.7 years for each additional cup per day.

Previous studies have suggested that smoking protects against development of blepharospasm, but this study did not show a significant protective effect.

"The most obvious candidate for the protective effect is caffeine, but the low frequency of decaffeinated coffee intake in Italy prevented us from examining the effects of caffeine on blepharospasm," the authors wrote.

Caffeine may block adenosine receptors, they proposed.

"Considering that the caffeine content of a cup of Italian coffee (60 to 120 mg) is similar to the average content of a cup of American coffee (95 to 125 mg), the protective effect on the development of bleph-arospasm might be exerted at caffeine doses greater than 120 to 240 mg, comparable with the caffeine doses suggested to be protective in Parkinson's disease," according to the authors.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
© 2025 MJH Life Sciences

All rights reserved.